Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.
Mov Disord. 2023 Sep;38(9):1736-1742. doi: 10.1002/mds.29516. Epub 2023 Jun 26.
Deep brain stimulation (DBS) has been increasingly used in the management of dyskinetic cerebral palsy (DCP). Data on long-term effects and the safety profile are rare.
We assessed the efficacy and safety of pallidal DBS in pediatric patients with DCP.
The STIM-CP trial was a prospective, single-arm, multicenter study in which patients from the parental trial agreed to be followed-up for up to 36 months. Assessments included motor and non-motor domains.
Of the 16 patients included initially, 14 (mean inclusion age 14 years) were assessed. There was a significant change in the (blinded) ratings of the total Dyskinesia Impairment Scale at 36 months. Twelve serious adverse events (possibly) related to treatment were documented.
DBS significantly improved dyskinesia, but other outcome parameters did not change significantly. Investigations of larger homogeneous cohorts are needed to further ascertain the impact of DBS and guide treatment decisions in DCP. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
深部脑刺激(DBS)已越来越多地用于治疗运动障碍性脑瘫(DCP)。关于长期疗效和安全性特征的数据很少。
我们评估苍白球 DBS 对 DCP 患儿的疗效和安全性。
STIM-CP 试验是一项前瞻性、单臂、多中心研究,来自母体试验的患者同意接受长达 36 个月的随访。评估包括运动和非运动领域。
最初纳入的 16 例患者中,有 14 例(平均纳入年龄 14 岁)进行了评估。在 36 个月时,(盲法)评定的总运动障碍损害量表评分有显著变化。记录了 12 例可能与治疗相关的严重不良事件。
DBS 显著改善了运动障碍,但其他结局参数无显著变化。需要对更大的同质队列进行研究,以进一步确定 DBS 的影响,并指导 DCP 的治疗决策。© 2023 作者。运动障碍由 Wiley Periodicals LLC 代表国际帕金森病和运动障碍协会出版。